NCT04508049Active, not recruiting
A Study to Evaluate Renal Fibrosis Using MRI Techniques
Quantitative Magnetization Transfer MRI for Evaluation of Renal Fibrosis
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate whether or not an MRI technique (quantitative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 6 Aug 2020
- Start date
- 1 Oct 2020
- Primary completion date
- Dec 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- High blood pressure
- NCT number
- NCT04508049
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From 1 Oct 2020 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients have clinically significant medical conditions within the prior six months: e.g. myocardial infarction, congestive heart failure, stroke, that would, in the opinion of the investigators, compromise the safety of the patient.
- Requirement for potentially nephrotoxic drugs; e.g., non-steroidal anti-inflammatory drugs.
- Kidney transplant.
Other illness
- Uncontrolled hypertension (Systolic BP \>180 mmHg despite therapy).
- Diabetes requiring insulin or oral hypoglycemic medications.
- Evidence of hepatitis B or C, or HIV infection.
- History of deep venous thrombosis within 3 months of enrollment.
- Any active malignancy and undergoing therapy
- Another known acute or chronic kidney disease
- Latex allergy
Lab values
- Patient has serum creatinine \>2.2 mg/dL for men and \>2.0 mg/dL for women (Caucasians); \>2.4 mg/dL for men and \>2.1 mg/dL for women (African American).
- Cardiac ejection fraction less than 30%.
Other
- RVD in a solitary kidney
- Pacemaker, implantable defibrillator or other contraindication to MRI
- Inability to comply with breath-hold for 20 seconds
- Patients are pregnant.
- Kidney or ureteric stone
- Federal medical center inmates.
Who the study is looking for
- Between ages 40 and 80 years old.
- Patients with hypertension (BP\>140/90 mmHg) and/or requirement for two or more antihypertensive medications for more than 4 weeks.
- Serum creatinine under 2.2 and 2.0 mg/dL for men and women, respectively (Caucasians). Values for African-American subjects are slightly higher (2.4 mg/dL, males; 2.1 mg/dL females).
- No contraindications to angiography: severe contrast allergy.
- No contraindications to no-contrast MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia.
- Patients have the ability to comply with protocol
- Patients are competent and able to provide written informed consent
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.